• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Hanger Announces Estimate of Certain Financial Results for 2021 and Provides Initial Financial Outlook for 2022

    2/7/22 4:05:00 PM ET
    $HNGR
    Medical Specialities
    Health Care
    Get the next $HNGR alert in real time by email

    Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced a preliminary estimate of certain results for the year ended December 31, 2021. The Company also provided its initial financial outlook for the year ended December 31, 2022.

    Preliminary 2021 Results

    The Company currently anticipates that its net revenues for the year ended December 31, 2021 will be approximately $1.120 billion, and Adjusted EBITDA for the same period to be approximately $118.9 million. This reflects growth of approximately 12 percent in net revenue and 13 percent in Adjusted EBITDA as compared to the year ended December 31, 2020. The Company's estimated Patient Care same clinic growth rate was approximately 9 percent on a day-adjusted basis.

    The above estimates regarding the results for the year ended December 31, 2021 are based on currently-available information, and are subject to change upon completion of the Company's financial statement closing and audit processes.

    Since the time of the Company's most recent discussion of the outlook for 2021 provided on November 8, 2021, its revenue has been adversely affected by the impact of the Omicron variant of COVID-19 on its patient visit trends and on its clinic operations. In addition to increased employee absences due to COVID-19, the Company's results have also been affected by labor shortages, primarily in administrative and technical roles, as well as increases in labor costs amidst the national labor shortage and inflationary environment.

    2022 Outlook

    The Company currently anticipates 2022 net revenue will be in a range between $1.190 billion and $1.220 billion, and Adjusted EBITDA in a range between $127 million and $132 million. This reflects growth of approximately 7 percent in revenue and 9 percent in Adjusted EBITDA over 2021, using the mid-point of the guidance ranges. The Company's revenue growth includes an estimate of approximately 5 percent in same clinic revenue growth on a day adjusted basis related to its Patient Care segment.

    The Company's outlook for 2022 includes approximately $35 million in revenue relating to the full year effect of acquisitions consummated in 2021.

    Adjusted EBITDA

    A reconciliation of GAAP and non-GAAP financial results for the year ended December 31, 2021 is included in Table 1 provided at the back of this press release. Adjusted EBITDA in the 2022 outlook is provided on a non-GAAP basis only because a reconciliation to the most comparable GAAP financial measure, Income Before Taxes, is not available without unreasonable effort due to the unpredictable nature of reconciling items that render such a reconciliation not meaningful for investors. Please refer to our most recent Form 10-Q as filed with the Securities and Exchange Commission for discussion of our use of Adjusted EBITDA in evaluating financial performance.

    Fourth Quarter and Full Year 2021 Conference and Webcast Details

    Hanger will report its financial results for the fourth quarter and the year ended December 31, 2021 after the stock market closes on Monday, February 28, 2022.

    Hanger's management team will host a conference call on Tuesday, March 1, 2022 at 8:30 a.m. Eastern time to discuss the Company's fourth quarter and full year 2021 financial results and outlook for 2022.

    To participate in the Company's live conference call, please dial (844) 200-6205 or +1 (929) 526-1599 for international participants and reference access code 124631. A live webcast, replay of the call, and earnings release will be available on the Company's Investor Relations website at https://investor.hanger.com/financial-reporting/quarterly-results. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.

    About Hanger, Inc. – Headquartered in Austin, Texas, Hanger, Inc. (NYSE:HNGR) provides comprehensive, outcomes-based orthotic and prosthetic (O&P) services through its Patient Care segment, with approximately 875 Hanger Clinic locations nationwide. Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. Rooted in 160 years of clinical excellence and innovation, Hanger is a purpose-driven company with a vision to lead the O&P markets by providing superior patient care, outcomes, services and value, aimed at empowering human potential. For more information on Hanger, visit investor.hanger.com.

    This earnings release contains statements that are forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include information concerning our liquidity and our possible or assumed future results of operations, including descriptions of our business strategies. These statements often include words such as "believe," "expect," "project," "potential," "anticipate," "intend," "plan," "estimate," "seek," "will," "may," "would," "should," "could," "forecasts" or similar words. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. We believe these assumptions are reasonable, but you should understand that these statements are not guarantees of performance or results, and our actual results could differ materially from those expressed in the forward-looking statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent releases or reports. These statements involve risks, estimates, assumptions, and uncertainties that could cause actual results to differ materially from those expressed in these statements and elsewhere in this release. These uncertainties include, but are not limited to, the financial and business impacts of COVID-19 on our operations and the operations of our customers, suppliers, governmental and private payers and others in the healthcare industry and beyond; federal laws governing the health care industry; governmental policies affecting O&P operations, including with respect to reimbursement; failure to successfully implement a new enterprise resource planning system or other disruptions to information technology systems; the inability to successfully execute our acquisition strategy, including integration of recently acquired O&P clinics into our existing business; changes in the demand for our O&P products and services, including additional competition in the O&P services market; disruptions to our supply chain; our ability to enter into and derive benefits from managed-care contracts; our ability to successfully attract and retain qualified O&P clinicians; labor shortages and increased turnover in our employee base; contractual, inflationary and other general cost increases, including with regard to costs of labor, raw materials and freight; and other risks and uncertainties generally affecting the health care industry. For additional information and risk factors that could affect the Company, see its Form 10-K for the year ended December 31, 2020 and Quarterly Reports on Form 10-Q for the three months ended March 31, 2021, June 30, 2021 and September 30, 2021, each as filed with the Securities and Exchange Commission. The information contained in this press release is made only as of the date hereof, even if subsequently made available by the Company on its website or otherwise.

    SOURCE Hanger, Inc.

    Table 1

    Hanger, Inc.

    Reconciliation of Income before Income Taxes to EBITDA and Adjusted EBITDA

    Preliminary Fiscal Year 2021 Estimated Results

    (Unaudited - in millions)

     

     

     

    Year Ended

    December 31, 2021

    Income before income taxes

     

    $

    43.1

     

     

     

     

    Adjustments to calculate EBITDA:

     

     

    Depreciation and amortization

     

     

    32.5

     

    Interest expense, net

     

     

    28.9

     

    Non-service defined benefit plan expense

     

     

    0.7

     

    Adjustments - net income to EBITDA

     

     

    62.1

     

    EBITDA (Non-GAAP)

     

     

    105.2

     

     

     

     

    Further adjustments to calculate Adjusted EBITDA:

     

     

    Equity-based compensation

     

     

    12.3

     

    Acquisition-related expenses

     

     

    0.9

     

    Hanger supply chain implementation costs

     

     

    0.4

     

    Severance expenses

     

     

    0.5

     

    Proceeds from grants under the CARES Act

     

     

    (1.1

    )

    Loss on cancellation of education event

     

     

    0.7

     

    Further adjustments - EBITDA to Adjusted EBITDA

     

     

    13.7

     

    Adjusted EBITDA (Non-GAAP)

     

    $

    118.9

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220207005652/en/

    Get the next $HNGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HNGR

    DatePrice TargetRatingAnalyst
    7/25/2022$24.00 → $18.75Buy → Hold
    Jefferies
    More analyst ratings

    $HNGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hanger, Inc. Completes Acquisition by Patient Square Capital

      Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced the completion of its previously announced transaction to be acquired by Patient Square Capital, a leading dedicated health care investment firm, in an all-cash transaction. The acquisition was previously announced on July 21, 2022, and Hanger's stockholders approved the transaction at a Special Meeting of Stockholders held on September 30, 2022. As a result of the completion of the acquisition, Hanger stockholders will receive $18.75 in cash per share of common stock, and Hanger's common stock will no longer be traded on the New York Stock Exchange (NYSE). Wit

      10/3/22 12:30:00 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • Hanger, Inc. Stockholders Approve Acquisition by Patient Square Capital

      Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced that its stockholders approved at a special meeting the acquisition of Hanger by Patient Square Capital, a leading dedicated health care investment firm. Vinit Asar, Hanger's President and Chief Executive Officer said, "I would like to express my gratitude to the Hanger stockholders for their support today, and throughout this transaction process. The Hanger team is excited about this partnership with Patient Square Capital, and beginning our next chapter as a private company. We believe this collaboration will enable us to accelerate our growth and enhance our

      9/30/22 4:05:00 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • Frontier Communications Set to Join S&P MidCap 400; Hain Celestial Group to Join S&P SmallCap 600

      NEW YORK, Sept. 27, 2022 /PRNewswire/ -- Frontier Communications Parent Inc. (NASD: FYBR) will replace The Hain Celestial Group Inc. (NASD:HAIN) in the S&P Midcap 400 and The Hain Celestial Group will replace Hanger Inc. (NYSE:HNGR) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, October 3. Patient Square Capital, LP. is acquiring Hanger in a deal expected to be completed soon pending final closing conditions. The Hain Celestial Group is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Se

      9/27/22 6:16:00 PM ET
      $FYBR
      $HAIN
      $HNGR
      $SPGI
      Telecommunications Equipment
      Telecommunications
      Packaged Foods
      Consumer Staples

    $HNGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Evolent Health Appoints Seth R. Frank as Vice President, Investor Relations

      WASHINGTON, Dec. 1, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Seth R. Frank has joined the company as Vice President, Investor Relations, effective immediately. Reporting to John Johnson, Evolent's Chief Financial Officer, Seth will lead Evolent's investor relations (IR) strategy and oversee its relationships with the investment community. "Seth provides a demonstrated track record of proactive, finance-driven leadership in health care investor relations to Evolent," said Evolent Health Chief Financial Officer John Johnson. "He brings long-ter

      12/1/21 8:00:00 AM ET
      $EVH
      $HNGR
      $MDRX
      Other Consumer Services
      Consumer Discretionary
      Medical Specialities
      Health Care

    $HNGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hanger downgraded by Jefferies with a new price target

      Jefferies downgraded Hanger from Buy to Hold and set a new price target of $18.75 from $24.00 previously

      7/25/22 7:27:44 AM ET
      $HNGR
      Medical Specialities
      Health Care

    $HNGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sullivan Kathryn M returned $1,162,988 worth of shares to the company (62,026 units at $18.75), closing all direct ownership in the company

      4 - HANGER, INC. (0000722723) (Issuer)

      10/4/22 5:25:47 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form 4: Jones Mark M returned $386,138 worth of shares to the company (20,594 units at $18.75), closing all direct ownership in the company

      4 - HANGER, INC. (0000722723) (Issuer)

      10/4/22 5:21:56 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form 4: Pettingill Richard returned $1,465,031 worth of shares to the company (78,135 units at $18.75), closing all direct ownership in the company

      4 - HANGER, INC. (0000722723) (Issuer)

      10/4/22 5:21:57 PM ET
      $HNGR
      Medical Specialities
      Health Care

    $HNGR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Hanger Inc.

      15-12G - HANGER, INC. (0000722723) (Filer)

      10/13/22 9:00:25 AM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by Hanger Inc.

      EFFECT - HANGER, INC. (0000722723) (Filer)

      10/7/22 12:15:11 AM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Hanger Inc.

      S-8 POS - HANGER, INC. (0000722723) (Filer)

      10/3/22 1:29:11 PM ET
      $HNGR
      Medical Specialities
      Health Care

    $HNGR
    Financials

    Live finance-specific insights

    See more
    • Hanger Reports Second Quarter 2022 Financial Results

      Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced its financial results for the second quarter and six months ended June 30, 2022. Financial Highlights Net revenues were $312.0 million for the three months ended June 30, 2022, compared to $280.8 million for the same period in 2021, reflecting growth of 11.1 percent. Patient Care same clinic revenue growth per day was 6.2 percent during the period. Net income was $10.1 million for the three months ended June 30, 2022, compared to $10.2 million for the same period in 2021. Income from operations was $20.8 million for the quarter compared to $20.1 million for

      8/8/22 4:05:00 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • Hanger, Inc. Announces Definitive Agreement to be Acquired by Patient Square Capital for $18.75 Per Share in Cash

      Total Enterprise Value of Approximately $1.25 Billion Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, announced today that it has entered into a definitive agreement to be acquired by Patient Square Capital, a dedicated health care investment firm. Under the terms of the agreement, which has been unanimously approved by Hanger's Board of Directors, Hanger stockholders will receive $18.75 in cash per share, representing an approximately 29% premium to the 30 calendar day volume-weighted average price (VWAP) ending July 20, 2022, and a total enterprise value of approximately $1.25 billion. Upon completion of the transaction,

      7/21/22 4:13:00 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • Hanger Announces Date of 2022 Second Quarter Earnings Release and Conference Call

      Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, announced it will report its financial results for the second quarter and six months ended June 30, 2022 after the stock market closes on Monday, August 8, 2022. Hanger's management team will host a conference call to discuss the second quarter 2022 financial results the following morning on Tuesday, August 9, 2022 at 8:30 a.m. Eastern time. To participate in the Company's live conference call, please dial (844) 200-6205 or +1 (929) 526-1599 for international participants and reference access code 020458. A live webcast, replay of the call and earnings release, will be availa

      7/7/22 8:00:00 AM ET
      $HNGR
      Medical Specialities
      Health Care

    $HNGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Hanger Inc. (Amendment)

      SC 13G/A - HANGER, INC. (0000722723) (Subject)

      11/8/22 11:20:47 AM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Hanger Inc. (Amendment)

      SC 13G/A - HANGER, INC. (0000722723) (Subject)

      8/10/22 2:56:04 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Hanger Inc. (Amendment)

      SC 13G/A - HANGER, INC. (0000722723) (Subject)

      8/8/22 10:36:46 AM ET
      $HNGR
      Medical Specialities
      Health Care